Dexamethasone blunts post-spinal hypotension in geriatric patients undergoing orthopedic surgery: a double blind, placebo-controlled study

Tarek Ashoor (✉ tarekashoor@med.asu.edu.eg)
Ain Shams University

Noha S. Hussien
Ain Shams University

Sherif G. Anis
Ain Shams University

Ibrahim M. Esmat
Ain Shams University

Research article

Keywords: Anesthesia, subarachnoid, Senile, Hemodynamics, Dexamethasone

DOI: https://doi.org/10.21203/rs.3.rs-54037/v2

License: ☐ ☑ This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: Post-spinal anesthesia (PSA) hypotension in elderly patients is challenging. Correction of PSA hypotension by fluids either colloids or crystalloids or by vasoconstrictors pose the risk of volume overload or compromising cardiac conditions. Dexamethasone is used to treat conditions manifested by decrease of peripheral vascular resistance. The research team was the first to test the hypothesis of its role in preventing or decreasing the incidence of PSA hypotension.

Methods: 110 patients, aged 60 years or more were recruited to receive a single preoperative dose of dexamethasone 8 mg IVI in 100 ml normal saline (D group) (55 patients) 2 hours preoperatively, and 55 patients were given placebo (C group) in a randomized, double-blind trial. Variations in blood pressure and heart rate in addition to the needs of ephedrine and/or atropine following spinal anesthesia (SA) were recorded. SA was achieved using subarachnoid injection of 3 ml hyperbaric bupivacaine 0.5%.

Results: Demographic data and the quality of sensory and motor block were comparable between groups. At 5th, 10th minutes post SA; systolic, diastolic and, mean arterial pressures were statistically significant higher in D group. At 20th minutes post SA; pressure readings and heart rate changes didn’t show any statistically significance between groups. The need for ephedrine and side effects were statistically significant lower in D group than C group.

Conclusion. Post spinal anesthesia hypotension, nausea, vomiting and shivering in elderly patients were less common after receiving a single preoperative dose of dexamethasone 8 mg IVI than control.

Registration number: Clinical Trials. gov Identifier: NCT 03664037Registered 17 September 2018 - Retrospectively registered, http://www.Clinical Trial.gov

Background

Spinal anesthesia (SA) is preferred by anesthetists in elderly patients however, its common and sometimes dangerous complications may limit its use. Hypotension and bradycardia are the most frequent complications reaching up to one-third in non-obstetric populations (1). The main cause of post spinal anesthesia (PSA) hypotension is the decrease in the sympathetic outflow causing arterial vasodilatation, a decrease in venous return and consequently the activation of the Bezold Jarish reflex (BJR) (2) that elicits a triad of bradycardia, vasodilatation and further hypotension (3,4). BJR is elicited by activation of 5-HT3 receptors within the intracardiac vagal nerve endings (5). Those effects are prominent in senile patients with PSA hypotension estimated to be over 70% (5). On the other hand, methods that are used to avoid the PSA hypotension (e.g., volume loading or vasopressor administration) may add the risk of hypervolemia and/or myocardial ischemia for those patients (6).

Dexamethasone (DEX) – a synthetic glucocorticoid- is used to abolish PSA nausea and vomiting (7) or PSA shivering (8), and may increase the duration of sensory block (9,10). DEX increases tissue peripheral
vascular resistance (PVR) in rats\(^\text{(11)}\) and humans by a variety of mechanisms\(^\text{(12)}\), and there is a plethora of studies confirming its role in maintaining the integrity of circulation in situations of intense vasodilatation like septic shock\(^\text{(13)}\) and anaphylaxis\(^\text{(14)}\). Moreover, glucocorticoids in general inhibit 5-HT\(_3\) expression and DEX was found to decrease the level of 5-HT\(_3\) in the cerebral cortex and hippocampus in developing rats\(^\text{(15)}\).

This study was conducted to evaluate the efficacy of a single preoperative dose of DEX intravenous infusion (IVI) to attenuate the PSA hypotension in geriatric patients undergoing orthopedic surgery.

**Methods**

The study protocol was approved by the institute ethics committee (FMASU R 46/ 2018) before enrollment of patients and a written informed consent was obtained by every patient. This randomized, prospective, double blind, study, adheres to CONSORT guidelines and was conducted at Ain-Shams university hospitals from the 1\(^{\text{st}}\) of March 2018 till the 31\(^{\text{st}}\) of August 2018 on 110 ASA I, II, III patients aged 60 years or more and scheduled for lower limb orthopedic surgeries under SA Patients with contraindication to SA (e.g. coagulopathy, thrombocytopenia, allergy to local anesthetic agent) and those on steroids or serotonin related medications (e.g. selective serotonin reuptake inhibitor) were excluded.

Randomization of the patients was performed using a computer-generated random numbers concealed in sealed opaque envelopes and a nurse randomly chose the envelope that determined the group of assignment. Patients were allocated into two equal groups (55 each) with 1:1 ratio according to post spinal hypotension prophylaxis; patients received either DEX 8 mg diluted in 100 ml 0.9% normal saline (NS) IVI over 15 min (D group) or an equal volume of plain NS (Control group) (C group) 2 h preoperatively. Study medications were prepared by the hospital pharmacy and given by anesthetists not involved in any other part of the study. Patients fasted 8 hours and were not intravenously hydrated before the procedure.

On arrival in the operating room, routine monitoring was applied, a venous access was established with a wide-bored cannula and patients were sedated by 1mg of midazolam IV. Infusion of NS solution was commenced not to exceed 400 mL during SA and for 20 minutes thereafter. SA was performed by injecting 3 ml of 0.5% hyperbaric bupivacaine solution (Marcaine® Spinal Heavy 0.5%; Sunny pivaicaine, Manufactured by Sunny Pharmaceutical - Cairo - Egypt) at L3-L4 or L4-L5 level using 25gauge Quincke spinal needle.

After completing the subarachnoid injection, patients were positioned supine. Sensory level (by alcohol swab) and motor block (Modified Bromage Score\(^\text{(16)}\)) was assessed every 5 minutes. Heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean blood pressure (MBP) were recorded before giving the study medications (base line) and then during SA every 5 minutes for 4 readings.
Hypotension was considered if there was 25% decrease below the baseline for MAP and was managed by 300 ml of NS solution with incremental intravenous 5 mg doses of ephedrine. Bradycardia was considered if the heart rate was less than 50 beats/min and was treated with atropine (0.01mg/kg) IV, only data before giving ephedrine and/or atropine were analyzed if they were given. The anesthetists who performed the spinal anesthesia and recorded the hemodynamic changes were unaware of the medications given to patients preoperatively.

The proportion of patients with hypotension at any time during the first 20 min after induction of the SA and before starting the surgical procedure was set as the primary outcome.

The research team considered all 4 measurements of each of 3 blood pressures (SBP, DBP, MAP) as secondary outcomes. The obtained blood pressures values at each study time point were compared to the minimal values recorded within the 20 minutes following the subarachnoid blockade. Surgical procedure, positioning of the patient or application of tourniquet was not allowed during the study period. The pattern of sensory and motor blocks, number of patients who needed atropine and/or ephedrine, Changes in HR among groups and associated side effects (e.g., nausea, vomiting and shivering) were considered as secondary outcomes.

**Statistical analysis**

Depending on Baig et al., 2017 (17) who found that the hypotension rate in ondansetron and normal saline groups were 7.5% and 28.3% respectively and assuming that the power= 0.80 and α =0.05 and by using PASS 11th release, the minimal sample size for an equal size controlled clinical trial was 50 in each group. We recruited 55 in each for possible attrition (18).

The collected data were coded, tabulated, and statistically analyzed using IBM SPSS statistics (Statistical Package for Social Sciences) software version 18.0, IBM Corp., Chicago, USA, 2009.

Descriptive statistics were done for quantitative data as minimum & maximum of the range as well as mean (SD) (standard deviation) for quantitative normally distributed data, while it was done for qualitative data as number and percentage.

Inferential analyses were done for quantitative variables using Shapiro-Wilk test for normality testing, independent t-test in cases of two independent groups and paired t-test in cases of paired data. In qualitative data, inferential analyses for independent variables were done using Chi square test for differences between proportions and Fisher’s Exact test for variables with small expected numbers. The level of significance was taken at P value < 0.050 is significant, otherwise is non-significant.

**Results**

Out of 136 patients were assessed for eligibility and 110 patients were analyzed; 55 in the D group and 55 in C group. Demographic data in the study population were comparable between groups with no
statistically significant differences between them. *(Table 1)*

Assessment was done after subarachnoid block and ended 20 minutes later. Number of segments above S1 was not statistically significantly lower in C group than in D group at 5th minute and afterwards. Number of segments above S1 significantly increased in both groups beginning from 5th minute and afterwards. Time to complete motor block was not statistically significantly shorter in D group than in C group. *(Table 2)*

SBP at 5th and 10th minutes were statistically significantly higher among D group than C group, while DBP and MBP at 5th, 10th, and 15th minutes were statistically significantly higher among D group than C group *(Table 3).* There weren’t statistically significant changes between groups in HR. *(Figure 2)*

Minimum readings in SBP, DBP and MBP were statistically significantly higher in D group than C group, while the minimum reading in HR shows no statistically significant differences between groups. *(Figure 3)*

The need of ephedrine was statistically significantly lower in D group (P= 0.025) than C group, while there were no statistically significant changes in the need of atropine (P= 0.303) or those who needed atropine and ephedrine (P= 0.429) between D and C groups. The time to ephedrine and/or atropine need was not statistically significant between groups. Nausea, vomiting and shivering were statistically significantly lower in D group than C group (P= 0.012, P= 0.032, P<0.001 respectively). *(Table 4)*

**Discussion**

This study demonstrated favorable response rates regarding the efficacy of a single preoperative dose of DEX 8mg IVI to attenuate the PSA hypotension in geriatric patients undergoing orthopedic surgery. The research team observed higher minimal values of systolic, diastolic and mean arterial pressures in DEX group with minimal effects on heart rate. As far as the authors know, they were the first to raise that observation and proposed that theory.

The investigators observed that patients who were on steroids for different reasons and had spinal anesthesia had favorable post spinal hemodynamic outcomes with minimal hypotension and accordingly minimal needs for vasoconstrictors. This proposed the theory of the value of administration of DEX for obtunding the PSA hypotension.

Different controlled trials failed to demonstrate the superiority of either general or neuroaxial anesthesia on the outcome in elderly patients. However, neuroaxial anesthesia benefits of minimizing surgical stress, reducing pulmonary compromise, superior pain control and reduction of total blood loss made it a well-accepted anesthetic option for geriatric patients *(19).* However, in elderly, SA is associated with 25–69% incidence of hypotension and decreased physiological reserve that if added to the associated cardiovascular ischemic and/or valvular disease make even brief episodes of uncorrected hypotension...
hardly tolerable and might cause detrimental consequences on their cardiac and mental compromised conditions \(^{(20)}\).

DEX is a potent synthetic glucocorticoid that has pure glucocorticoid activity \(^{(12)}\). It increases PVR by a variety of mechanisms i.e. decreases vasodilator nitric oxide (NO), increases sympathetic activity and elevates plasma dopamine and plasma epinephrine. It also increases the sensitivity of vascular endothelium to different vasoconstrictors. \(^{(12)}\) Moreover, it has an anti 5HT\(_3\) effects which might influence BJR \(^{(12)}\). Those two effects hit exactly the two pathophysiological effects incriminated in eliciting post spinal hypotension \(^{(2)}\), explained our results and confirmed our conclusion (Figure 4). The timing and the administration of a preoperative single dose of dexamethasone IVI was based on a meta-analysis study conducted by De Oliveira et al., \(^{(7)}\).

Methods to alleviate post spinal hypotension either physical e.g. leg wrapping, elastic stockings, optimizing patient's position, or pharmacological e.g. intravenous fluids and vasopressors have been used with varying degree of success \(^{(21)}\). The usual measures of pre-load or co-load of either crystalloid or colloid remain controversial with many studies that confirm that post spinal hypotension remains significant regardless of the type or timing of the given fluids \(^{(21)}\) and may cause hypervolemia \(^{(6)}\). Infusion of crystalloid solutions results in its redistribution to extravascular compartment and induces atrial natriuretic peptide secretion which might augment lowering blood pressure because of its natriuretic, diuretic, and vasodilatory effects \(^{(22)}\). Infusion of colloid solutions on the other hand, despite remaining in intravascular space for a longer duration, is not popular routinely due to its increased cost, possibility of derangement of coagulation, suppression of platelet activity and the risk of anaphylaxis \(^{(23)}\). When it comes to vasoconstrictors, they cause tachycardia and hypertension which may worsen associated myocardial ischemia \(^{(24)}\).

The study of Owczuk et al., documented that administration of intravenous ondansetron (5HT\(_3\) blocker) prior to spinal anesthesia in geriatric patients attenuated the drop in the diastolic and mean arterial pressure without substantially affecting the systolic blood pressure. However, meta-analysis studies fail to confirm the validity of those conclusions based on low quality of evidence and insufficient evidence \(^{(25)}\). Moreover, ondansetron might be responsible for lower spinal block level and early recovery from spinal anesthesia. \(^{(26)}\)

In concordant with our study, Chu et al., \(^{(15)}\) confirmed that dexamethasone (with 5-HT3 blocking properties) similarly reduced the PONV risks as has been shown with other 5-HT3 receptor antagonists e.g. ondansetron. Concomitant with our results, Moeen et al., \(^{(8)}\) reported that intrathecal dexamethasone was as effective as intrathecal meperidine in attenuation of PSA shivering compared to placebo in patients scheduled for prostate surgery under spinal anesthesia with less adverse events. Adding to this, Shalu et al., concluded that administration of DEX 8 mg IV prolonged the duration of sensory block and postoperative analgesia in patients undergoing lower segment cesarean section under spinal anesthesia \(^{(9)}\).
This study had some limitations namely; the relatively small sample size and the restriction of the study duration to 20 minutes post spinal. However, the investigators chose to restrict the time of study to the time of maximum hemodynamic instability and before other influences e.g. tourniquet, skin incision or, bleeding occur. Glycemic profile in the hours after dexamethasone administration, the rate of infection and the postoperative delirium should have been reported.

The study however had many merits; the most important of which was the redirection of the medical society towards using dexamethasone which offers a cheap, an available and a simple pharmacological strategy to prevent post spinal hypotension, a common complication of spinal anesthesia, which can lead to serious events. Moreover, dexamethasone can be used also for the prevention of postoperative nausea and vomiting, the prevention of post spinal shivering and as antalgic adjuvant.

**Conclusion**

A single preoperative dexamethasone 8 mg IVI attenuated postspinal hypotension in geriatric patients undergoing orthopedic surgeries.

**Abbreviations**

SA: spinal anesthesia; PSA: postspinal anesthesia; BJR: Bezold Jarish reflex; 5HT3: 5-hydroxytryptamine receptor type 3; DEX: Dexamethasone; PVR: peripheral vascular resistance; ASA: American Society of Anesthesiologists; SNOSE: ratio in opaque and sealed envelope; NSS: normal saline; I.V.: Intravenous; HR: Heart rate; SBP: systolic blood pressure, DBP: diastolic blood pressure; MBP: mean blood pressure; SD: standard deviation; NO: nitric oxide.

**Declarations**

**Funding:** Study equipments were provided by Ain-shams University resources.

**Registration number:** Clinical Trials.gov Identifier: NCT 03664037Registered 17 September 2018 - Retrospectively registered, [http://www.Clinical Trial.gov](http://www.Clinical Trial.gov)

**The authors have disclosed no conflicts of interest.**

**Implication statement:** The research team validated the efficacy of a single preoperative dose of dexamethasone 8 mg intravenous infusion in attenuating post spinal anesthesia hypotension in geriatric patients undergoing orthopedic surgery.

**Ethics approval and consent to participate**

Ethical approval from Ain Shams University hospitals research committee was obtained (FMASU R 46/2018). Written informed consent was taken from all the patients, their parents or their guardians before any study procedure was conducted.
Consent for publication

Not applicable.

Availability of data and materials

The data that support the findings of this study are available from Ain Shams university hospitals and they are not publicly available. Data are however available from the corresponding author on reasonable request after permission of Ain Shams university.

Competing interests

The authors declared that they had no competing interests.

Authors’ contributions

T.A and I.M.E. were responsible for the conception and design of the study, analysis of the data, writing the manuscript and revising the manuscript. N.H. and S.A were responsible for clinical cases handling, collect the data and search the database. All authors have read and approved the manuscript.

Acknowledgements

The research team would thank residents of anesthesia and the nursing staff working in main operation theater, Ain-Shams University Hospitals for their valuable help in this work.

Authors' Information

1-Tarek Mohamed Ashoor: Lecturer, MD, Department of Anesthesia and Intensive Care, Faculty of Medicine, Ain-shams, Cairo, Egypt, Corresponding author Tel: +20 01092241039, Email: tarekashoor@med.asu.edu.eg

2- Noha Sayed Hussien: Assistant Professor, MD, Department of Anesthesia and Intensive Care, Faculty of Medicine, Ain-shams University, Cairo, Egypt. Email: nohasayedhussien@med.asu.edu.eg

3-Sherif George Anis: Assistant Professor, MD, Department of Anesthesia and Intensive Care, Faculty of Medicine, Ain-shams University, Cairo, Egypt. Email: sherifganis@hotmail.com

4-Ibrahim Mamdouh Esmat: Assistant Professor, MD, Department of Anesthesia and Intensive Care, Faculty of Medicine, Ain-shams University, Cairo, Egypt. Email: Ibrahim_mamdouh@med.asu.edu.eg

References

1. Heesen M, Klimek M, Hoeks SE, Rossaint R: Prevention of Spinal Anesthesia-Induced Hypotension During Cesarean Delivery by 5-Hydroxytryptamine-3 Receptor Antagonists: A Systematic Review and Meta-analysis and Meta-regression. Anesth Analg. 2016; 123(4):977-88.
2. Liu SS, McDonald SB: Current issues in spinal anesthesia. Anesthesiology. 2001; 94(5):888-906.
3. Campagna JA, Carter C: Clinical relevance of the Bezold-Jarisch reflex. Anesthesiology. 2003; 98(5):1250-60.
4. Rahbun JB, Raizada V, Severson ES, Huang A, Ling C, Rustagi T, et al. Polyethylene Glycol-Based Bowell Preparation Induced Episodic Sinus Arrest: The Bezold-Jarisch Reflex. American Journal of Gastroenterology: October 2019 – volume 114- Issue – p S1678.
5. Owczuk R, Wenski W, Twardowski P, Dylczyk-Sommer A, Sawicka W, Wujtewicz MA, et al.: Ondansetron attenuates the decrease in blood pressure due to spinal anesthesia in the elderly: a double blind, placebo-controlled study. Minerva Anestesiol. 2015; 81(6):598-607.
6. Messina A, Frassanito L, Colombo D, Vergari A, Draisic G, Della Corte, et al. Hemodynamic changes associated with spinal and general anesthesia for hip fracture surgery in severe ASA III elderly population: a pilot trial. Minerva Anestesiol. 2013; 79(9):1021-9.
7. De Oliveira GS Jr., Almeida MD, Benzon HT, McCarthy RJ. Perioperative single dose systemic dexamethasone for postoperative pain: A meta-analysis of randomized controlled trials. Anesthesiology 2011; 115:575-88.
8. Moeen SM, Moeen AM. Intrathecal dexamethasone vs. meperidine for prevention of shivering during transurethral prostatectomy: a randomized controlled trial. Acta Anaesthesiol Scand. 2017 Aug;61(7):749-757.
9. Shalu PS, Ghodki PS: To Study the Efficacy of Intravenous Dexamethasone in Prolonging the Duration of Spinal Anesthesia in Elective Cesarean Section. Anesth Essays Res. 2017; 11(2):321-325.
10. Albrecht E, Kern C, Kirkham KR: A systematic review and meta-analysis of perineural dexamethasone for peripheral nerve blocks. Anesthesia 2015; 70(1):71-83.
11. Ong SL, Zhang Y, Sutton M, Whitworth JA: Hemodynamics of dexamethasone-induced hypertension in the rat. Hypertens Res. 2009; 32(10):889-94.
12. Ong SLH, Zhang Y, Whitworth JA. Mechanisms of Dexamethasone-Induced Hypertension. Current Hypertension Review, 2009, 5, 61-71.
13. Fang F, Zhang Y, Tang J, Lunsford LD, Li T, Tang R, et al. Association of Corticosteroid Treatment with Outcomes in Adult Patients with Sepsis: A Systematic Review and Meta-analysis. JAMA Intern Med. 2019; 179(2):213-223.
14. Liyanage CK, Galappaththy P, Seneviratne SL. Corticosteroids in Management of Anaphylaxis; A Systematic Review of Evidence. Eur Ann Allerhy Clin Immunol. 2017; 49(5):196-207.
15. Chu CC, Hsing CH, Shieh JP, Chien CC, Ho CM, Wang JJ. The cellular mechanisms of the antiemetic action of dexamethasone and related glucocorticoids against vomiting. Eur J Pharmacol. 2014 Jan 5; 722:48-54.
16. Bromage PR.: A comparison of the hydrochloride and carbon dioxide salts of lidocaine and prilocaine in epidural analgesia. Acta Anaesthesiol Scand Suppl. 1965; 16:55-69.
17. Baig R, Shah AA, Khurshid T, Abid L, Tariq Z.: Use of Ondansetron for Prevention of Spinal Induced Hypotension. JIMDC.2017; 6(4):1-6.
18. Chung Chow S; Shao J, Wang H.: Sample Size Calculations in Clinical Research, 1stNew York:Marcel Dekker, Inc.;2003.
19. Atanas G. Sivevski, Dafina Karadjova, Emilia Ivanov and Andrijan Kartalov: Neruaxial Anesthesia in the Geriatric Patient. Frontiers in Medicine; 2018
20. Bendini C, Angelini A, Salsi F, Finelli ME, Martini E, Neviani F, et al. Relation of neurocardiovascular instability to cognitive, emotional and functional domains. Arch Gerontol Geriatr. 2007; 44 Suppl 1:69-74.
21. Bajwa SJ, Kulshrestha A, Jindal R.: Co-loading or pre-loading for prevention of hyopotension after spinal anesthesia! a therapeutic dilemma Anesth Essays Res. 2013 May-Aug;7(2):155-9.
22. Haj-Jang Ni, Hua-vueLiu, Juan Zhang, Ke Peng, Fu-Hai Ji : Crystalloid co-load reduced the incidence of hyopotension in spinal anesthesia for Cesarean delivery, when compared to crystalloid preload: A mea-analysis. Biomed Res Int. 2017; 2017: 3462529.
23. Chooi C,Cox JJ, Lumb RS, Middleton P, Chemali M, Emmett RS, et al. Techniques for preventing hyopotension during spinal anesthesia for caesarean section. Cochrane Database Syst Rev. 2020 Jul 1; 7:CD002251.
24. Bhagat H, Malhotra K, Ghildyal SK, Srivastava PC. Evaluation of preload and vasoconstricctors as a combined prophylaxis for hyopotension during subarachnoid anesthesia. Indian J. Anesth. 2004; 48(4): 229-303.
25. Terkawi AS, Mavridis D, Flood P, Wetterslev J, Terkawi RS, Bin Abdulhak AA, et al. Does Ondansetron Modify sympathectomy due to subarachnoid anesthesia? Meta-analysis, Mea-regression, and Trial sequential analysis. Anesthesiology. 2016 Apr;124(4):846-69.
26. Singh A, Singh CS, Kannaujia A, Agrawal J, Patel, ML, Verma AK: Effect of ondansetron on sensory level produced by intrathecal bupivacaine. International Journal of Basic & Clinical Pharmacology. 2015 ; 4(3): 561-564.
27. Tsubota S, Adachi N, Chen J, Yorozuya T, Nagaro T, Arai T. Dexamethasone changes brain monoamine metabolism and aggravates ischemic neuronal damage in rats. Anesthesiology. 1999 Feb;90(2):515-23.
28. Inoue T, Koyama T. Effects of acute and chronic administration of high-dose corticosterone and dexamethasone on regional brain dopamine and serotonin metabolism in rats. Prog Neuropsychopharmacol Biol Psychiatry. 1996 Jan; 20(1):147-56.

Tables

Table (1): Demographic and baseline clinical characteristics among the studied cases.
| Variables                                      | D Group (n=55) | C Group (n=55) | P-value |
|------------------------------------------------|----------------|----------------|---------|
| Age; years                                     | 75.8 (5.4)     | 75.6 (5.0)     | ^0.826  |
| Sex; male/female                               | 22/33          | 25/30          | #0.563  |
| Weight; kg                                     | 67.7 (3.8)     | 66.8 (3.2)     | ^0.217  |
| Height; cm                                     | 167.3 (4.3)    | 166.4 (4.9)    | ^0.316  |
| ASA; I, II, III; n                             | 4/ 38/ 13      | 7/ 33/ 15      | #0.519  |
| Ischemic heart disease (IHD); n                | 33             | 39             | #0.229  |
| Diabetes Mellitus (DM); n                      | 20             | 21             | #0.844  |
| Renal impairment; n                            | 11             | 10             | #0.808  |
| Hypertension (HTN); n                          | 42             | 45             | #0.482  |
| Anti hypertensive medications; n               | 42             | 45             | #0.482  |
| · Beta-Blockers                                | 36             | 40             | #0.409  |
| · ACE                                          | 29             | 32             | #0.565  |
| · ARBs                                         | 7              | 8              | #0.781  |
| · CCB                                          | 6              | 5              | #0.751  |
| Valvular heart diseases; n                     | 15             | 12             | #0.506  |
| · Aortic stenosis (mild)                       | 5              | 4              | §0.999  |
| · Aortic stenosis (moderate)                   | 4              | 3              | §0.999  |
| · Mitral regurgitation (moderate)              | 6              | 5              | #0.751  |
| Surgical procedure                             |                |                |         |
| · Total hip                                    | 13             | 15             | §0.839  |
| · Total Knee                                   | 14             | 12             |         |
| · Hip hemi-arthroplasty                        | 17             | 14             |         |
| · DHS                                          | 11             | 14             |         |

*Angiotensin II receptor blockers (ARBs), Dynamic Hip Screw (DHS).* ^Independent t-test. #Chi square test. §Fisher’s Exact test.

Table (2): Sensory and motor blocks among the studied cases.
| Variables                          | D Group (n=55) | C Group (n=55) | Difference (D-C) | ^P-value (groups) | #P-value (versus minute-5) |
|-----------------------------------|----------------|----------------|------------------|-------------------|--------------------------|
| Number of segments above S1       |                |                |                  |                   |                          |
| 5th minute                        | 4.0 (0.8)      | 3.8 (0.7)      | 0.2 (0.2)        | -0.1–0.5          | 0.174                    | --                       |
| 10th minute                       | 5.5 (0.8)      | 5.2 (1.0)      | 0.3 (0.2)        | 0.0–0.7           | 0.056                    | <0.001*                  |
| 15th minute                       | 6.7 (0.9)      | 6.4 (0.9)      | 0.2 (0.2)        | 0.0–0.6           | 0.167                    | <0.001*                  |
| 20th minute                       | 7.0 (0.8)      | 6.7 (0.6)      | 0.2 (0.1)        | 0.0–0.5           | 0.097                    | <0.001*                  |
| Time to complete motor block      |                |                |                  |                   |                          |
| **Time (minutes)**                | 7.1 (0.8)      | 7.4 (0.9)      | -0.3 (0.2)       | -0.6–0.1          | 0.126                    | --                       |

^Independent t-test. #Paired t-test. *Significant.

Table (3): Blood pressure changes among the studied cases.
| Variables | D Group | C Group | Difference (D-C) | P-value | P-value (versus baseline) |
|-----------|---------|---------|----------------|---------|--------------------------|
|           | (n=55)  | (n=55)  | Mean (SE) | 95% CI   |                          |
| SBP (mmHg) |         |         |           |         |                          |
| Baseline  | 147.9 (7.5) | 147.9 (8.0) | 0.1 (1.5) | -2.9–3.0 | 0.951 --                 |
| 5th minute | 142.3 (10.2) | 133.7 (15.2) | 8.6 (2.5) | 3.7–13.5 | 0.001* <0.001*           |
| 10th minute | 139.8 (9.5) | 134.7 (9.9) | 5.1 (1.9) | 1.3–9.0 | 0.009* <0.001*           |
| N=52, 47 |         |         |           |         |                          |
| 15th minute | 137.2 (9.3) | 135.0 (8.2) | 2.2 (1.9) | -1.5–5.9 | 0.246 <0.001*           |
| N=50, 41 |         |         |           |         |                          |
| 20th minute | 134.1 (8.3) | 132.1 (6.9) | 2.0 (1.7) | -1.3–5.3 | 0.236 <0.001*           |
| N=48, 38 |         |         |           |         |                          |
| Minimum | 131.4 (10.6) | 125.2 (13.3) | 6.2 (2.3) | 1.7–10.8 | 0.008* <0.001*           |
| DBP (mmHg) |         |         |           |         |                          |
| Baseline  | 86.8 (6.1) | 86.5 (6.6) | 0.4 (1.2) | -2.0–2.8 | 0.753 --                 |
| 5th minute | 77.8 (7.5) | 72.6 (9.2) | 5.1 (1.6) | 2.0–8.3 | 0.002* <0.001*           |
| 10th minute | 75.4 (6.7) | 70.5 (7.6) | 4.9 (1.4) | 2.0–7.7 | 0.001* <0.001*           |
| N=52, 47 |         |         |           |         |                          |
| 15th minute | 72.5 (7.7) | 67.8 (8.1) | 4.7 (1.7) | 1.4–8.0 | 0.006* <0.001*           |
| N=50, 41 |         |         |           |         |                          |
| 20th minute | 67.8 (6.9) | 65.7 (7.1) | 2.1 (1.5) | -0.9–5.1 | 0.174 <0.001*           |
| N=48, 38 |         |         |           |         |                          |
| Minimum | 66.6 (7.3) | 63.0 (7.9) | 3.6 (1.5) | 0.7–6.5 | 0.015* <0.001*           |
## MBP (mmHg)

|        | Baseline | 5th minute | 10th minute | 15th minute | 20th minute | Minimum |
|--------|----------|------------|-------------|-------------|-------------|---------|
| N      | 52, 47   | 50, 41     | 50, 41      | 48, 38      |             |         |
| MBP (mmHg) | 107.2 (6.5) | 99.3 (8.3) | 96.9 (7.4)  | 94.0 (8.1)  | 89.9 (7.0)  | 88.2 (8.0) |
| Baseline MBP | 106.9 (7.0) | 93.0 (11.1) | 91.9 (8.2)  | 90.2 (8.0)  | 87.8 (6.9)  | 83.7 (9.2)  |
| MBP | 0.3 (1.3) | 6.3 (1.9)  | 5.0 (1.6)   | 3.8 (1.7)   | 2.1 (1.5)   | 4.5 (1.6) |
| Minimum MBP | -2.3–2.8 | 2.6–10.0   | 1.8–8.1     | 0.5–7.2     | -1.0–5.1    | 1.2–7.7  |
| Standard deviation | 0.826 | 0.001* | <0.001* | 0.002* | <0.001* | 0.008* |

^Independent t-test. #Paired t-test. *Significant

**Table (4):** Atropine and ephedrine needs and associated side effects among groups.
| Variables                      | D Group (n=55) | C Group (n=55) | P-value   | RR (95% CI) |
|-------------------------------|----------------|----------------|-----------|-------------|
| **Hemodynamic supports**      |                |                |           |             |
| Atropine; n,%                 | 7 (12.7%)      | 11 (20.0%)     | #0.303    | 0.64 (0.27–1.52) |
| Ephedrine; n,%                | 8 (14.5%)      | 18 (32.7%)     | #0.025*   | 0.44 (0.21–0.94) |
| Atropine and Ephedrine; n,%   | 7 (12.7%)      | 10 (18.2%)     | #0.429    | 0.70 (0.29–1.71) |
| Time needed for atropine (minute), (n=7,11) | 8.6 (3.8)   | 7.7 (3.4)     | ^0.631    |             |
| Time needed for ephedrine (minute), (n=8,18) | 10.6 (5.6)  | 9.2 (4.6)     | ^0.493    |             |
| **Associated side effects**   |                |                |           |             |
| Nausea; n,%                   | 7 (12.7%)      | 18 (32.7%)     | ^0.012*   | 0.39 (0.18–0.86) |
| Vomiting; n,%                 | 1 (1.8%)       | 8 (14.5%)      | ^0.032*   | 0.13 (0.02–0.97) |
| Shivering; n,%                | 7 (12.7%)      | 25 (45.5%)     | ^<0.001*  | 0.28 (0.13–0.59) |

**Figures**
Figure 1

Flow chart of the study.
Figure 2

Changes in HR among groups.
Figure 3

a) Minimum HR, b) Minimum SBP, c) Minimum DBP, d) Minimum MBP changes between groups.
Figure 4

Possible mechanisms of Dexamethasone in alleviating spinal anesthesia induced hypotension.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- CONSORTChecklist.docx